Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sundrug CoTSE:9989 -0.13%76 EV-to-EBIT is 9.14 as of Aug. 22, 2026, which is 13% below its 10-year median of 10.48. GuruFocus rates TSE:9989 with a GF Score™ of 76/100 and a GF Value™ of 円4,766.05 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 474 Healthcare Providers & Services companies, Sundrug Co ranks better than 76.79% on this metric.
The historical rank and industry rank for Sundrug Co's EV-to-EBIT or its related term are showing as below:
TSE:9989'
s EV-to-EBIT Range Over the Past 10 Years
Min: 6.62 Med: 10.48 Max: 16.32
Current: 9.13
During the past 13 years, the highest EV-to-EBIT of Sundrug Co was 16.32. The lowest was 6.62. And the median was 10.48.
TSE:9989's EV-to-EBIT is ranked better than 76.79% of 474
companies
in the Healthcare Providers & Services industry
Industry Median: 15.845
vs TSE:9989: 9.13
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sundrug Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円435,096 Mil.
Sundrug Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円46,062 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sundrug Co EV-to-EBIT Related Terms
Sundrug Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sundrug Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Sundrug Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sundrug Co EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sundrug Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sundrug Co's EV-to-EBIT falls into.
Sundrug Co's current Enterprise Value is 円420,853 Mil.
Sundrug Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円46,062 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sundrug Co (TSE:9989) has a EV-to-EBIT of 9.14 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sundrug Co and its competitors. This is 13% below median its historical median of 10.48. Over the past decade, Sundrug Co's EV-to-EBIT has ranged from 6.62 to 16.32. According to the industry distribution chart, Sundrug Co ranks #110 out of 474 companies in the Healthcare Providers & Services industry, placing it in the top 23.2%.
Is Sundrug Co's EV-to-EBIT too high?
Sundrug Co's current EV-to-EBIT of 9.14 is 13% below median its 10-year median of 10.48. Over the past 10 years, this metric has ranged from a low of 6.62 to a high of 16.32. The Healthcare Providers & Services industry median EV-to-EBIT is 15.85. Sundrug Co's value of 9.14 is 42.3% below this industry median. Based on the distribution chart, Sundrug Co ranks #110 out of 474 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sundrug Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sundrug Co's EV-to-EBIT compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sundrug Co ranks #110 out of 474 companies for EV-to-EBIT. This places Sundrug Co in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.85. Sundrug Co's value of 9.14 is 42.3% below this benchmark. Historically, Sundrug Co's own EV-to-EBIT has ranged from 6.62 to 16.32 over the past decade. While the company's 10-year median is 10.48 vs. the industry median of 15.85, Sundrug Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.85, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sundrug Co's current EV-to-EBIT of 9.14 is 42.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sundrug Co and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sundrug Co's current EV-to-EBIT is 9.14, which is 13% below median its own 10-year median of 10.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sundrug Co stock overvalued right now?
Based on GuruFocus' analysis, Sundrug Co (TSE:9989) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,766.05, compared to a current price of 円3,712.00 — trading 22.1% below its estimated fair value. The current EV-to-EBIT is 9.14, which is 13% below median its 10-year median of 10.48 and 42.3% below the Healthcare Providers & Services industry median of 15.85. Sundrug Co's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sundrug Co (TSE:9989), the current EV-to-EBIT is 9.14 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sundrug Co (TSE:9989) Overvalued in 2026?
Based on GuruFocus' analysis, Sundrug Co stock appears to be undervalued.
The current stock price of 円3,712.00 is trading 22.1% below its estimated GF Value™ of 円4,766.05.
GuruFocus considers Sundrug Co to be Modestly Undervalued.
Key valuation signals for TSE:9989:
EV-to-EBIT: 9.14 (13% below median its 10-year median of 10.48)
GF Value™: 円4,766.05 vs. price of 円3,712.00 (22.1% below fair value)
Industry Position: 42.3% below the Healthcare Providers & Services median (#110 of 474)
No single metric tells the full story. See the TSE:9989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sundrug Co Ltd is a Japanese-based company engaged in the operation of drug stores and discount stores. The Group operates through two segments: the Drug Store Business, which mainly sells pharmaceuticals, cosmetics, and daily necessities, and the Discount Store Business, which mainly sells food products, household goods, and other related items. It generates the majority of its revenue from the Drugstore business segment.
76GF Score
Get the complete analysis for TSE:9989
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9989 has been successfully added to your 
